Clinical trials: Contraceptives, Oral, Combined
Acne Vulgaris
GA YAZ ACNE in China Phase III
The purpose of this study is to evaluate the efficacy and safety of YAZ (drospirenone 3 mg / ethinylestradiol 20 µg) in comparison with placebo in female patients with moderate acne vulgaris over 6 treatment cycles.
- Trial name
- NCT00818519
- Testing
- EE20/Drospirenone (YAZ, BAY86-5300)
- Where
- 7 sites in China
- Volunteers
- 179 people
- Sponsor
- Bayer
Healthy
A Study in Healthy Women to Test Whether BI 425809 Influences the Amount of a Contraceptive in the Blood
The main objective of this trial is to investigate the possible effect of multiple oral doses of BI 425809 on the steady state pharmacokinetics of ethinylestradiol (EE) and levonogestrel (LNG) (administered as the combined oral…
- Trial name
- NCT05613777
- Testing
- Microgynon®, Iclepertin
- Where
- Germany
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Tuberculosis
A Study to Investigate the Pharmacokinetics of a Combined Oral Contraceptive When Given Alone and in Combination With GSK3036656 in Female Participants of Non-childbearing Potential Aged 18 to 65 Years of Age
The purpose of this study is to provide data showing if there are any effects of GSK3036656 on a combined oral contraceptive containing Ethinyl Estradiol (EE) and Levonorgestrel (LNG), which will help inform future studies on…
- Trial name
- NCT06354257
- Testing
- Microgynon, GSK3036656
- Where
- Spain
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Contraception
E4 FREEDOM (Female Response Concerning Efficacy and Safety of Estetrol/Drospirenone as Oral Contraceptive in a Multicentric Study) - United States/Canada Study
The objectives of this study are to evaluate the contraceptive efficacy, vaginal bleeding pattern (cycle control), and the general safety and acceptability of the 15 mg estetrol (E4)/3 mg drospirenone (DRSP) combination in…
- Trial name
- NCT02817841
- Testing
- 15 mg E4/3 mg DRSP
- Where
- 2 sites in United States, Canada
- Volunteers
- 2,148 people, healthy volunteers welcome
- Sponsor
- Estetra
Pregnancy Prevention
A Study to Evaluate the Efficacy and Safety of DR-103 for the Prevention of Pregnancy
This is an open-label, single-treatment study. All subjects will receive 12 months of oral contraceptive therapy with DR-103. Study participants will receive physical and gynecological exams, including Pap smear.
- Trial name
- NCT00996580
- Testing
- DR-103
- Where
- 94 sites in United States
- Volunteers
- 3,597 people, healthy volunteers welcome
- Sponsor
- Teva Women's Health
Contraceptive Usage, Overweight or Obesity
A 6-month Observational Study on Combined Oral Contraceptives and Body Weight in Pre-Menopausal Women With Overweight or Obesity
Approximately 15 million women of reproductive age women in the United States have overweight or obesity and use the combined estrogen and progestin oral contraceptive pill (COC).
- Conditions
- Contraceptive Usage, Overweight or Obesity, Body Weight Changes, Appetitive Behavior
- Trial name
- NCT05061472
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- University of Colorado, Denver
Chronic Hepatitis C
Study to Assess the Effect of BMS-790052 on the Pharmacokinetics of Ortho Tri-Cyclen® in Healthy Female Subjects
The purpose of this study is to assess the effect of BMS-790052 on the pharmacokinetics of Ortho Tri-Cyclen® in healthy female subjects.
- Trial name
- NCT00983957
- Testing
- BMS-790052, Ortho Tri-Cyclen®
- Where
- 3 sites in United States, Canada
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Contraception
Effects on Bone Mineral Density (BMD) of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing LNG/EE (292005)(P05765)(COMPLETED)
The primary purpose of this study is to evaluate the effects of the NOMAC-E2 combined oral contraceptive (COC) on bone mineral density (BMD).
- Trial name
- NCT00511342
- Testing
- NOMAC-E2, LNG-EE
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Organon and Co
Bone; Disorder, Development and Growth
Effects of Oral vs. Non-oral Contraceptives on the GH/IGF-1 Axis
This study will determine whether the negative effects of combined oral contraceptive (COC) therapy on the growth hormone/insulin-like growth factor-1 (GH/IGF-1) axis and bone turnover are dependent on the route of administration…
- Trial name
- NCT02367833
- Testing
- Combined Oral Contraceptive, Transdermal Contraceptive, Contraceptive Vaginal Ring
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Penn State University
Contraception
Study of the Contraceptive Efficacy and Safety of a NOMAC-E2 Combined Oral Contraceptive (COC)(P06448)
The purpose of this study was to assess the contraceptive efficacy of a nomegestrol acetate + 17ß-estradiol (NOMAC-E2) combined oral contraceptive (COC) in healthy, sexually-active American women at risk for pregnancy.
- Trial name
- NCT01656434
- Testing
- NOMAC-E2, NETA-EE, ethinylestradiol (EE)
- Volunteers
- 3,173 people, healthy volunteers welcome
- Sponsor
- Organon and Co
Contraception
Effects on Hemostasis, Lipids, Carbohydrate Metabolism, Adrenal & Thyroid Function of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing LNG-EE (292004)(COMPLETED)(P05764)
The primary purpose of this study is to evaluate the effects of the combined oral contraceptive (COC) NOMAC-E2 on hemostasis, lipids, carbohydrate metabolism, adrenal function, and thyroid function.
- Trial name
- NCT00511355
- Testing
- NOMAC-E2, Levonorgestrel and Ethinyl Estradiol
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- Organon and Co
Contraception
LCS12 vs Combined Oral Contraceptive (COC) User Satisfaction Study
The primary objective of this study is to evaluate user satisfaction and tolerability in young women (18-29 years of age) using the LCS12 compared with young women using a COC (Yasmin) over a period of 18 months.
- Trial name
- NCT01254292
- Testing
- Levonorgestrel IUD (LCS, BAY86-5028), Yasmin (EE30/DRSP, BAY86-5131)
- Where
- 94 sites in United States, Austria and 3 more
- Volunteers
- 567 people
- Sponsor
- Bayer
Epilepsy
Effect of BIA 2-093 on the Pharmacokinetics of a Combined Oral Contraceptive.
Single centre, two-way crossover, randomised, open-label study in 20 healthy female volunteers.The volunteers received an oral single-dose of a combined contraceptive containing with an oral once daily dose of 1200 mg of BIA 2-093
- Trial name
- NCT02281448
- Testing
- BIA 2-093, Contraceptives, Oral, Combined
- Where
- Portugal
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Abnormal Uterine Bleeding, Unspecified, Uterine Bleeding Heavy
Treatment of Unacceptable Bleeding Patterns in ETG Implant Users With an Oral Contraceptive
This double-blinded, placebo-controlled, randomized trial will compare the effects of the use of a combined oral contraceptive pill to a placebo pill for women who are experiencing irregular and/or heavy bleeding associated with…
- Trial name
- ROBI (NCT01963403)
- Testing
- EE 30mcg/LNG 150mcg
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- University of California, Davis
Contraception
Efficacy and Safety of Etonogestrel + 17β-Estradiol Vaginal Ring and Levonorgestrel-Ethinyl Estradiol Combined Oral Contraceptive in Adult Women at Risk for Pregnancy (MK-8342B-062)
The purpose of this study is to assess the contraceptive efficacy of the etonogestrel + 17β-estradiol (ENG-E2) vaginal ring in women between 18 and 35 years of age based on the number of in-treatment pregnancies as expressed by…
- Trial name
- NCT02616146
- Testing
- ENG-E2 125 μg/300 μg vaginal ring, LNG-EE 150 μg/30 μg COC
- Where
- 14 sites in Austria, Costa Rica and 12 more
- Volunteers
- 2,016 people, healthy volunteers welcome
- Sponsor
- Organon and Co
HIV Infections
Effect of GSK3640254 on the Pharmacokinetics of a Combination Oral Contraceptive
This is an open-label, single-sequence, 1-way drug-drug interaction study to investigate the effect of GSK3640254 on the pharmacokinetics of a combination oral contraceptive containing ethinyl estradiol (EE) and levonorgestrel…
- Trial name
- NCT03984825
- Testing
- GSK3640254, Portia
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Contraception, HIV
Protease Inhibitors and Combined Oral Contraceptive Pharmacokinetics and Pharmacodynamics
The project is a two-arm prospective cohort and pharmacokinetic study comparing levonorgestrel and ethinyl estradiol pharmacokinetics in HIV-positive women taking antiretroviral regimens that include ritonavir to those in women…
- Trial name
- NCT02531321
- Testing
- Levonorgestrel and Ethinyl Estradiol
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Southern California
Tubal Patency
HSG and Tubal Patency Study
The investigators' research group is working to develop a highly effective, low cost non-surgical method of permanent contraception for women.
- Trial name
- NCT02146248
- Testing
- combined oral contraceptive, DepoProvera
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Jeffrey Jensen
Contraception
Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive
The purpose of this study is evaluating Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive in Premenopausal Females Aged 14 to 35 Years (Inclusive).
- Trial name
- NCT05264506
- Testing
- NOMAC-E2 COC
- Where
- 103 sites in United States
- Volunteers
- 3,055 people
- Sponsor
- Organon and Co
Solid Cancers
A Study of Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists
This is a single-arm, multicenter, Phase Ib study designed to describe the effect of GDC-0449 on the pharmacokinetics of rosiglitazone and oral contraceptives in patients with advanced solid tumors who are refractory to treatment…
- Trial name
- NCT01209143
- Testing
- Vismodegib, Rosiglitazone, Norethindrone/ethinyl estradiol
- Where
- 3 sites in United States
- Volunteers
- 52 people
- Sponsor
- Genentech, Inc.